CERo Therapeutics Holdings Inc. (OTCQB: CERO) completed dosing and the 28-day dose-limiting toxicity assessment period for three patients in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE